Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 233Head and Neck Neoplasms 150Squamous Cell Carcinoma of Head and Neck 136Stomach Neoplasms 117Lung Neoplasms 109Esophageal Neoplasms 90Uterine Cervical Neoplasms 72Neoplasms 67Urinary Bladder Neoplasms 56Breast Neoplasms 48Ovarian Neoplasms 46Esophageal Squamous Cell Carcinoma 45Pancreatic Neoplasms 44Small Cell Lung Carcinoma 42Neoplasm Metastasis 40Adenocarcinoma Of Esophagus 38Carcinoma, Squamous Cell 33Carcinoma, Ovarian Epithelial 32Mesothelioma, Malignant 30Parkinson Disease 4, Autosomal Dominant Lewy Body 28Lymphoma 28Adenocarcinoma of Lung 25Sarcoma 24Cholangiocarcinoma 24Nasopharyngeal Carcinoma 22Carcinoma 22Unspecified Adult Solid Tumor, Protocol Specific 21Neuroblastoma 21Gallbladder Neoplasms 21Central Nervous System Neoplasms 21

Interventions

toripalimab 2sintilimab 2Surveys and Questionnaires 1Pemetrexed 1Paclitaxel 1Injections 1Etoposide 1Docetaxel 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Lung Cancer × Cisplatin × Clear all
NCT05664971 2025-12-02

JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer

Shanghai Junshi Bioscience Co., Ltd.

Phase 1/2 Completed
119 enrolled
Thoracic

Advanced Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡